Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.
2024年11月27日，特拉華州威明頓（GLOBE NEWSWIRE）——Prelude Therapeutics Incorporated（prelude therapeutics）（納斯達克：PRLD）一家臨床階段的精準腫瘤醫療公司，今天宣佈該公司將參加於2024年12月2日以虛擬形式舉行的Citizens JMP證券血液學和腫瘤學峯會。
On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat.
12月2日星期一，美國東部時間上午11時30分，Prelude首席執行官Kris Vaddi博士和總裁兼首席醫療官Jane Huang博士將參加火邊聊天。
A live webcast of the fireside chat can be accessed on the Company's website under Events and Presentations. The recording will be archived and available on the Company's website for 90 days.
火邊聊天的現場網絡廣播可以在公司網站的活動和演示下找到。 錄音將存檔，並在公司網站上提供90天。
About Prelude Therapeutics
關於Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
Prelude Therapeutics是一家領先的精準腫瘤學公司，致力於爲癌症患者在高未滿足需求領域開發創新藥物。我們的研發項目包括幾個新型候選藥物，包括首創、高選擇性的IV和口服SMARCA2降解劑，以及潛在的一流CDK9抑制劑。我們還利用我們在靶向蛋白降解方面的專業知識，與合作伙伴共同發現、開發和商業化下一代蛋白降解抗體偶聯物（精準ADC）。我們的使命是將精準醫學的承諾延伸到每一個有需求的癌症患者。欲了解更多信息，請訪問preludetx.com。
Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com
投資者聯繫：
Robert Doody
高級副總裁，投資者關係。
prelude therapeutics
484.639.7235
RDoody@preludetx.com
譯文內容由第三人軟體翻譯。